Clinical studies investigating the effect of vitamin E therapy in patients with NASH
Sebastian Larion M.D.,Sandeep Khurana M.B.B.S.
First published: 31 January 2018
DOI: 10.1002/cld.687
Abstract
Watch a video presentation of this article
Full Text
Nonalcoholic steatohepatitis (NASH) is the inflammatory sequelae of fatty liver disease that is characterized histologically by steatosis with ballooning degeneration and lobular hepatitis. NASH and particularly fibrosis development are significantly associated with increased all-cause and liver-related mortality.[1, 2] By 2030, NASH is projected to affect more than 27 million patients in the United States and be attributed to 10.9% of all patient deaths.[3] Despite this major public health burden, no U.S. Food and Drug Administration–approved medications exist for the specific treatment of NASH, identifying an unmet need for a further understanding of disease-causing processes.
No comments:
Post a Comment